Stock Ticker: BSX (Boston Scientific Corp.)
Current Market Context: Boston Scientific Corp. (BSX) reported its financial results for the fourth quarter, providing guidance for the first quarter and full-year 2026. The company anticipates adjusted earnings growth and net sales expansion, with analysts’ expectations aligned with the projections.
BSX Initiates Guidance for Q1 and FY 2026
Medical devices company Boston Scientific Corp. (BSX) unveiled its adjusted earnings and sales growth estimates for the first quarter of 2026. The company forecasts adjusted earnings of $0.78 to $0.80 per share, with net sales growth expected to range from 10.5 to 12.0 percent. Analysts predict earnings of $0.80 per share on revenue growth of 11.57 percent to $5.20 billion for the quarter.
Outlook for Fiscal 2026
Looking ahead to fiscal 2026, Boston Scientific Corp. (BSX) projects adjusted earnings between $3.43 and $3.49 per share, with net sales growth anticipated to be around 10.5 to 11.5 percent. The Street’s consensus estimates stand at earnings of $3.47 per share on revenue growth of 11.55 percent to $22.39 billion for the year.
In pre-market trading on the NYSE, BSX is currently priced at $90.00, experiencing a decline of $1.59 or 1.74 percent.
For more financial updates and earnings reports, visit rttnews.com
